Ascentage Pharma Group International (NASDAQ:AAPG) Sees Strong Trading Volume – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw an uptick in trading volume on Thursday. 8,929 shares were traded during trading, an increase of 30% from the average daily volume of 6,863 shares. The stock last traded at $14.80 and had previously closed at $14.98.

Analyst Ratings Changes

Several research firms recently issued reports on AAPG. Citizens Jmp assumed coverage on Ascentage Pharma Group International in a report on Tuesday, October 13th. They issued a “market outperform” rating and a $35.00 price objective on the stock. Citigroup assumed coverage on Ascentage Pharma Group International in a research report on Wednesday, October 14th. They issued a “buy” rating and a $46.00 target price for the company. JPMorgan Chase & Co. reduced their price target on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research report on Thursday, October 8th. William Blair assumed coverage on shares of Ascentage Pharma Group International in a research note on Friday, October 16th. They issued an “outperform” rating for the company. Finally, BTIG Research restated a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Two analysts have rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $43.90.

Ascentage Pharma Group International Trading Down 4.3%

The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22. The firm has a 50-day moving average price of $15.85 and a two-hundred day moving average price of $20.20.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $22.24 million for the quarter. Equities analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 EPS for the current year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.